Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net income (loss)	$ (1,980)	$ (1,920)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Gain on sale of in process research and development	(144)	(2,139)
Stock-based compensation expense	354	1,348
Changes in operating assets and liabilities:
Prepaid expenses and other assets	1,994	358
Accounts payable, accrued expenses and other	(87)	(496)
Net cash provided by (used in) operating activities	137	(2,849)
Cash flows from investing activities
Net proceeds from sale of in process research and development	144	2,139
Net cash provided by investing activities	144	2,139
Cash flows from financing activities
Proceeds from exercise of stock options	239
Repayment of debt		(56)
Net cash provided by (used in) financing activities	239	(56)
Net increase (decrease) in cash and cash equivalents	520	(766)
Cash and cash equivalents, beginning of period	14,038	16,580
Cash and cash equivalents, end of period	$ 14,558	$ 15,814